Ana sayfa
Piyasalar
Grafikler ve fikirler
Algo
Haberler
Store
Aracı kurumlar
İndir
Ekonomik Takvim
Alım-satım sinyalleri
Web Terminali
Arama yapmak için
/
tuşuna basın: @kullanıcı, $sembol, ...
Ara
Giriş yap
Hesap oluştur
Türkçe
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Français
Italiano
IMCR
#1803
Immunocore Holdings plc American Depositary Shares
32.300
0
+2.28%
Sektör:
Baz:
Kar para birimi:
Günlük aralık
Yıllık aralık
Günlük değişim
+2.28%
Aylık değişim
-8.00%
6 aylık değişim
-3.52%
Yıllık değişim
-3.52%
Önceki kapanış
31.580
0
Open
32.300
0
Bid
Ask
Low
32.300
0
High
32.300
0
Hacim
17
Piyasalar
ABD hisse senetleri
Sağlık hizmetleri
IMCR
Open full chart
Financials
Overview
Rapor
Statistics
Dividends
Quarterly
Annual
Income statement
Balance sheet
Cash flow
Value
2020
2021
2022
2023
2024
2025
Total assets
—
—
—
597 M
1.01 B
1.07 B
Total liabilities
—
—
—
228.16 M
648.79 M
686.24 M
Total equity
—
—
—
368.84 M
360.72 M
381.03 M
Total liabilities & shareholders' equities
—
—
—
597 M
1.01 B
1.07 B
Total debt
—
—
—
—
—
—
Net debt
—
—
—
—
—
—
Immunocore Holdings plc - American Depositary Shares
Immunocore is a global commercial-stage biotechnology company, based in Oxfordshire, which researches and develops biological drugs using soluble T-cell receptor technology.
Haberler
Immunocore Holdings plc 2025 Q4 - Results - Earnings Call Presentation (NASDAQ:IMCR) 2026-02-25
Immunocore Holdings plc (IMCR) Q4 2025 Earnings Call Transcript
Immunocore Holdings kazancı $0,40 ile beklentilere göre daha kötü, kâr ise beklentilere göre düşük
Immunocore Holdings earnings missed by $0.40, revenue fell short of estimates
JAZZ Stock Rises as Q4 Earnings & Sales Top Expectations
RXRX Q4 Loss Narrower Than Expected, Revenues Increase Y/Y, Stock Up
Repligen's Q4 Earnings Beat Estimates, Revenues Surge Y/Y
Apellis Q4 Loss Wider Than Expected, Revenues Decline Y/Y
Immunocore melanom hattını ilerletirken kazanç açıklayacak
Immunocore earnings ahead as melanoma pipeline advances
Madrigal Q4 Earnings Miss, MASH Drug Sales Drive Top Line, Stock Down
Immunocore (IMCR) Upgraded to Strong Buy: Here's Why